Terms: = Lung cancer AND SMARCD1, CRACD1, 6602, ENSG00000066117, Rsc6p, BAF60A, Q96GM5 AND Treatment
3 results:
1. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT; Buse JB; Liebovitz DM; Nicklas JM; Puskarich MA; Cohen K; Belani HK; Anderson BJ; Huling JD; Tignanelli CJ; Thompson JL; Pullen M; Wirtz EL; Siegel LK; Proper JL; Odde DJ; Klatt NR; Sherwood NE; Lindberg SM; Karger AB; Beckman KB; Erickson SM; Fenno SL; Hartman KM; Rose MR; Mehta T; Patel B; Griffiths G; Bhat NS; Murray TA; Boulware DR;
Lancet Infect Dis; 2023 Oct; 23(10):1119-1129. PubMed ID: 37302406
[TBL] [Abstract] [Full Text] [Related]
2. MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor smarcd1.
Hong CF; Lin SY; Chou YT; Wu CW
J Biol Chem; 2016 Jan; 291(4):1877-1889. PubMed ID: 26542803
[TBL] [Abstract] [Full Text] [Related]
3. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S; Crawford J; Chang A; Manegold C; Perez-Soler R; Douillard JY; Thatcher N; Barlesi F; Owonikoko T; Wang Y; Pultar P; Zhu J; Malik R; Giaccone G;
Ann Oncol; 2013 Nov; 24(11):2875-80. PubMed ID: 24050956
[TBL] [Abstract] [Full Text] [Related]
